Evidence map›Paper›PMID 40504416›Full record

ReviewJournal of gastroenterology2025

The 2024 diagnostic criteria for primary sclerosing cholangitis.

Itaru Naitoh, Hiroyuki Isayama, Nobuhisa Akamatsu, Suguru Mizuno, Toshio Fujisawa, Nobuhiro Nakamoto, Yousuke Nakai, Shuichiro Umetsu, Mitsuyoshi Suzuki, Shintaro Yagi and 6 more

Abstract readReview
In one paragraph

Review in Journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Itaru NaitohDepartment of Gastroenterology, Nagoya City University Midori Municipal Hospital, Nagoya, Japan.
Hiroyuki IsayamaDepartment of Gastroenterology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo City, Tokyo, 113-8421, Japan. h-isayama@juntendo.ac.jp.ORCID 0000-0002-3308-9326
Nobuhisa AkamatsuArtificial Organ and Transplantation Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Suguru MizunoDepartment of Gastroenterology and Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Toshio FujisawaDepartment of Gastroenterology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo City, Tokyo, 113-8421, Japan.
Nobuhiro NakamotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Yousuke NakaiDepartment of Internal Medicine, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
Shuichiro UmetsuDepartment of Pediatric Hepatology and Gastroenterology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan.
Mitsuyoshi SuzukiDepartment of Pediatrics, Juntendo University Faculty of Medicine, Tokyo, Japan.
Shintaro YagiDepartment of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kanazawa University, Kanazawa, Japan.
Hironori HagaDepartment of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
Kenji NotoharaDepartment of Anatomic Pathology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
Katsuhiro SanoDepartment of Radiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Susumu TazumaJR Hiroshima Hospital, Hiroshima, Japan.
Takahiro NakazawaDepartment of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Atsushi TanakaDepartment of Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Funding

Japan Intractable Diseases Research Foundation JPMH23FC1015
6 · The paper itself

Abstract

Primary sclerosing cholangitis (PSC) is an idiopathic chronic cholestatic disease with a poor prognosis. As there were no specific biomarkers for diagnosing PSC, we developed diagnostic criteria in 2016 based on cholangiography and elevated biliary enzymes. Novel findings and knowledge have subsequently accumulated, and we now propose the 2024 diagnostic criteria, to overcome several limitations of the 2016 diagnostic criteria. The Intractable Hepato-Biliary Diseases Study Group in Japan of the Committee of Research on Measures for Intractable Diseases established a working group consisting of experts in PSC comprising gastroenterologists, endoscopists, hepatologists, liver-transplant surgeons, pediatric hepatologists, pathologists, and radiologists. This working group proposed the 2024 diagnostic criteria after several discussions and public hearings. There are additional diagnostic targets; small duct PSC, pediatric PSC, and PSC recurrence following liver transplantation differ from the 2016 diagnostic criteria, which were for diagnosing large duct PSC in adults. The 2024 diagnostic criteria facilitate the use of magnetic resonance cholangiography in addition to endoscopic retrograde cholangiography in imaging, and incorporate gamma-glutamyl transferase for evaluating cholestasis to diagnose pediatric patients. Furthermore, PSC recurrence following liver transplantation can be diagnosed based on a liver biopsy and characteristic biliary findings. We hope that the 2024 diagnostic criteria will help not only hepatologists treating adults but also general physicians, pediatric hepatologists, and liver-transplant surgeons who manage patients with various forms of PSC.

Indexed as

Cholangitis, SclerosingAdultChildCholangiographyCholangiopancreatography, Endoscopic RetrogradeCholangiopancreatography, Magnetic Resonancegamma-GlutamyltransferaseHumansJapanLiver TransplantationRecurrencegamma-GlutamyltransferaseDiagnostic criteriaLarge duct primary sclerosing cholangitisPrimary sclerosing cholangitisRecurrence following liver transplantationSmall duct primary sclerosing cholangitis

Identifiers

PMID40504416
PMCPMC12450801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.